0
Investigators have devised a novel therapeutic method for treating glioblastomas post-surgery by using stem cells taken from healthy donors engineered to attack GBM-specific tumor cells. This strategy demonstrated profound efficacy in preclinical models of GBM, with 100 percent of mice living over 90 days after treatment.